Lushang Freda Pharmaceutical Co (SHSE:600223) Cyclically Adjusted Revenue per Share: ¥8.68 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600223 Lushang Freda Pharmaceutical Co Ltd SHSE:600223
73 GF Score
Price ¥5.67
GF Value ¥6.58
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lushang Freda Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Lushang Freda Pharmaceutical Co SHSE:600223 -0.35% 73 Cyclically Adjusted Revenue per Share is ¥8.68 as of Mar. 2026. GuruFocus rates SHSE:600223 with a GF Score™ of 73/100 and a GF Value™ of ¥6.58 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lushang Freda Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥0.847. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥8.68 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Lushang Freda Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -2.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lushang Freda Pharmaceutical Co was 15.00% per year. The lowest was -2.80% per year. And the median was 7.05% per year.

As of today (2026-08-14), Lushang Freda Pharmaceutical Co's current stock price is ¥5.67. Lushang Freda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥8.68. Lushang Freda Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.65.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lushang Freda Pharmaceutical Co was 2.26. The lowest was 0.47. And the median was 0.97.


Lushang Freda Pharmaceutical Co  (SHSE:600223) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lushang Freda Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.67/8.68
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lushang Freda Pharmaceutical Co was 2.26. The lowest was 0.47. And the median was 0.97.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lushang Freda Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Lushang Freda Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lushang Freda Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lushang Freda Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Lushang Freda Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.66 9.45 9.27 8.93 8.69

Lushang Freda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.94 8.91 8.98 8.69 8.68

Lushang Freda Pharmaceutical Co Cyclically Adjusted Revenue per Share Competitor Comparison

For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lushang Freda Pharmaceutical Co Cyclically Adjusted PS Ratio vs Real Estate Industry

For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lushang Freda Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600223
73GF Score
Lushang Freda Pharmaceutical Co Ltd SHSE:600223
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lushang Freda Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lushang Freda Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.847/116.3033*116.3033
=0.847

Current CPI (Mar. 2026) = 116.3033.

Lushang Freda Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.765 101.400 0.877
201609 1.872 102.400 2.126
201612 3.347 102.600 3.794
201703 0.776 103.200 0.875
201706 1.585 103.100 1.788
201709 1.391 104.100 1.554
201712 4.573 104.500 5.090
201803 0.904 105.300 0.998
201806 1.865 104.900 2.068
201809 2.964 106.600 3.234
201812 2.907 106.500 3.175
201903 1.291 107.700 1.394
201906 2.728 107.700 2.946
201909 2.881 109.800 3.052
201912 3.384 111.200 3.539
202003 1.349 112.300 1.397
202006 2.239 110.400 2.359
202009 3.428 111.700 3.569
202012 6.359 111.500 6.633
202103 1.689 112.662 1.744
202106 2.219 111.769 2.309
202109 2.255 112.215 2.337
202112 5.698 113.108 5.859
202203 1.341 114.335 1.364
202206 3.210 114.558 3.259
202209 3.408 115.339 3.437
202212 3.008 115.116 3.039
202303 1.279 115.116 1.292
202306 1.190 114.558 1.208
202309 0.838 115.339 0.845
202312 1.259 114.781 1.276
202403 0.905 115.227 0.913
202406 1.063 114.781 1.077
202409 0.825 115.785 0.829
202412 1.137 114.893 1.151
202503 0.864 115.116 0.873
202506 0.963 114.907 0.975
202509 0.751 115.471 0.756
202512 0.929 115.832 0.933
202603 0.847 116.303 0.847

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥8.68 mean?
Lushang Freda Pharmaceutical Co (SHSE:600223) has a Cyclically Adjusted Revenue per Share of ¥8.68 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lushang Freda Pharmaceutical Co and its competitors.
Is Lushang Freda Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Lushang Freda Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥8.68. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to competitors?
Lushang Freda Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥8.68 can be compared against companies in the Real Estate industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Real Estate company?
A good Cyclically Adjusted Revenue per Share depends on the Real Estate industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lushang Freda Pharmaceutical Co and its competitors. Lushang Freda Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥8.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.58, compared to a current price of ¥5.67 — trading 13.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥8.68. Lushang Freda Pharmaceutical Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current Cyclically Adjusted Revenue per Share is ¥8.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?

Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥5.67 is trading 13.8% below its estimated GF Value™ of ¥6.58. GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600223:

  • Cyclically Adjusted Revenue per Share: ¥8.68
  • GF Value™: ¥6.58 vs. price of ¥5.67 (13.8% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lushang Freda Pharmaceutical Co Business Description

Address No. 9777 Jingshi Road, Building 5, Lixia District, Jinan City, CHN
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
73GF Score

Get the complete analysis for SHSE:600223

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.67
Price
¥6.58
GF Value